Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Recognizing and Treating VTE in Patients with Cancer – Bridging Guideline-Based Recommendations with Real-World Evidence

Release Date: February 27, 2020
Expiration Date: February 27, 2021
Media: Internet - based

Activity Overview

As cancer incidence rates remain high, so does the risk of disease- or treatment-related complications, such as venous thromboembolism (VTE), leading to devastating functional losses and even death. In fact, VTE, comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs 4- to 7-fold higher in patients with cancer compared with the general population. Because several different types of cancer are associated with a higher risk of clot formation, management of VTE requires a multidisciplinary approach to treatment and prophylaxis. It is imperative for oncologists and hematologists to have knowledge of VTE risk factors and stratification, management strategies using low-molecular weight heparins or direct oral anticoagulants, guideline-based recommendations for care, and methods for reducing recurrence following initial treatment.

Acknowledgment of Support

This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Complete the activity in its entirety.
  • Complete the post-activity assessment.
  • Complete the evaluation and request credit.
  • Learners may immediately download a CME certificate upon successful completion of these steps.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Recognize the prevalence, morbidity, and mortality rates as well as risk factors associated with development of VTE in patients with cancer.
  • Apply recent evidence-based guideline recommendations for the prevention and treatment of cancer-associated VTE into clinical practice.
  • Identify strategies for the prevention and treatment of VTE in patients with cancer, including the reduction of risk of recurrence following initial treatment.
  • Implement individualized anticoagulation regimens for prevention and treatment of VTE in patients with cancer that are based on the unique needs and characteristics of each patient.

Faculty, Staff, and Planners’ Disclosures


Sagar Lonial
Sagar Lonial, MD, FACP
Anne and Bernard Gray Family Professor and Department Chair
Department of Hematology and Medical Oncology
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant Research Support: Celgene, Janssen, Takeda; Consultant: Celgene, Novartis, Bristol-Myers Squibb, Takeda, Janssen, GlaxoSmithKline, Amgen, AbbVie.

Kenneth A. Bauer
Kenneth A. Bauer, MD
Professor of Medicine and Hematologist
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
Boston, MA

Disclosures: Consultant: Janssen.

Simon Mantha
Simon Mantha, MD, MPH
Associate Attending Physician and Hematologist
Hematology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Other: Daboia Consulting LLC.

This activity was written by PER® editorial staff under faculty guidance and review.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By